Trimethoprim-sulfamethoxazole

Mayo Clinic Proceedings

Volumn 74, Issue 7, 1999, Pages 730-734

  Smilack, Jerry D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; FOLIC ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL PERITONITIS; CONFERENCE PAPER; DIARRHEA; DRUG INDICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NAUSEA; NOCARDIOSIS; PNEUMOCYSTOSIS; SIDE EFFECT; VOMITING; WEGENER GRANULOMATOSIS;

EID: 0033033406     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.7.730     Document Type: Conference Paper

References (46)

1. Wormser GP, Keusch 6T. Trimethoprim-sulfamethoxazole in the United States. Ann Intern Med 1979;91:420-429
2. Finland M. Combinations of antimicrobial drugs: trimethoprimsulfamethoxazole [editorial]. N EnglJ Med 1974;291:624-627
3. Burchall JJ. Mechanism of action of trimethoprim-sulfamethoxazole. II. J Infect Dis 1973;128(Suppl):437-441
4. Huovlnen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis 1997;24(Suppl 1):S63-S66
5. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999:281:736-738
6. Bactrim. In: Physicians' Desk Reference. 52nd ed. Montvale (NJ): Medical Economics; 1998. pp 2438-2440
7. Centers for Disease Control and Prevention. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997;46(RR-12):l-46
8. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc 1996;71:5-13
9. Sepkowltz KA. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? Mayo Clin Proc 1996:71:102-103
10. Lundstrom TS, Sobel JD. Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Infect Dis Clin North Am 1995 Sep;9:747767
11. Stegeman CA, Tervaert JWC, de Jong PE, Kallenberg CGM. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N EnglJ Med 1996:335:1620
12. DeRemee RA. Empiricism and Wegener's granulomatosis [editorial]. N Engl J Med 1996;335:54-55
13. Relnhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996;89:1523
14. Stegeman CA, Cohen Tervaert JW, Kallenberg CG. Co-trimoxazole and Wegener's granulomatosis: more than a coincidence? [editorial]. Nephrol Dial Transplant 1997:12:652-655
15. Slngh N, Gayowski T, Yu VL, Wagener MM. Trimethoprimsulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995:122:595598
16. Lemer PI. Nocardiosis. Clin Infect Dis 1996:22:891-903
17. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al (Infectious Diseases Society of America). 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997:25:551-573
18. Gonzales LA, Hill HR. Advantages and disadvantages of antimicrobial prophylaxis in chronic granulomatous disease of childhood. Pediatr Infect Dis J 1988:7:83-85
19. Levitz RE, Qulntlllani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984:100:881-890
20. Lorber B. Listeriosis. Clin Infect Dis 1997;24:l-9
21. Stamm WE, Hooton TM. Management of urinary tract infections in adults. NEnglJMed 1993:329:1328-1334
22. Hooton TM, Winter C, Tlu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995:273:41-45
23. Goodgame RW. Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, isospora, and cyclospora. Ann Intern Med 1996:124:429-441
24. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrlson G, Singer I, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 4th ed. Philadelphia: American College of Physicians-American Society of Internal Medicine; 1999
25. Lee BL. Drug interactions and toxicities in patients with AIDS. In: Sande MA, Volberding PA, editors. The Medical Management of AIDS. 5th ed. Philadelphia: Saunders; 1997. pp 125-142
26. Veenstra J, Veugelers PJ, Keet IP, van der Ven AJ, Mledema F, Lange JM, et al. Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. Clin Infect Dis 1997;24: 936-941
27. Smith CL, Brown I, Torraca BM. Acetylator status and tolerance of high-dose trimethoprim-sulfamethoxazole therapy among patients infected with human immunodeficiency virus. Clin Infect Dis 1997;25: 1477-1478
28. Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprimsulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995:20:849-853
29. Nguyen MT, Weiss PJ, Wallace MR. Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1995; 9:573-575
30. Cortese LM, Soucy DM, Endy TP. Trimethoprim/sulfamethoxazole desensitization. Ann Pharmacother 1996;30:184-186
31. Belchl-Hernandez J, Espinosa-Parra FJ. Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection. Ann Allergy Asthma Immunol 1996:76:355-358
32. Palusci VJ, Kaul A, Lawrence RM, Haines KA, Kwittken PL. Rapid oral deserialization to trimethoprim-sulfamethoxazole in infants and children. Pediatr Infect Dis J 1996:15:456-460
33. Caumes E, Guermonprez G, Lecomte C, Katlama C, Bricalre F.
34. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol 1997:133:465-469
35. Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprimsulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993:119:291-295
36. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996:124:316-320
37. Perazella MA, Mahnensmlth RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996:46:187-192
38. Elllson DH. Hyperkalemia and trimethoprim-sulfamethoxazole. Am J Kidney Dis 1997;29:959-962
39. Velazquez H, Perazella MA, Wright FS, Elllson DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993:119:296-301
40. Naderer 0, Nafzlger AN, Bertlno JS Jr. Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother 1997:41:2466-2470
41. Pashankar D, McArdle M, Robinson A. Co-trimoxazole induced aseptic meningitis. Arch Dis Child 1995:73:257-258
42. Blumenfeld H, Cha JH, Cudkowicz ME. Trimethoprim and sulfonamide-associated meningoencephalitis with MRI correlates. Neurology 1996:46:556-558
43. Jurado R, Carpenter SL, Rlmland D. Case reports: trimethoprimsulfamethoxazole-induced meningitis in patients with HIV infection. Am J Med Sei 1996:312:27-29
44. Gregg CR. Drug interactions and anti-infective therapies. Am J Med 1999:106:227-237
45. Committee on the Safety of Medicines/Medicines Control Agency. Revised indications for co-trimoxazole (Septrin, Bactrim, various generic preparations). Curr Probl Pharmacovigil 1995;21:6
46. Co-trimoxazole use restricted. Drug Ther Bull 1995:33:92-93